Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Zydus Cadila Healthcare Acquires US Company
Zydus Pharmaceuticals USA Inc., through its subsidiary Zynesher Pharmaceuticals USA LLC
has entered into an agreement to acquire the assets of the US based pharmaceutical
company Nesher Pharmaceuticals Inc. Nesher operates as the generic subsidiary of KV
Pharmaceutical,based at St. Louis, Missouri, USA. The financial details of the agreement
are undisclosed.
Nesher has considerable expertise in niche therapies which have development or
production barriers, such as controlled release medications or DEA-controlled substances.
The broad-based assets purchase agreement includes assets and assumption of certain
liabilities, Nesher’s existing and pipeline ANDAs, certain manufacturing facilities and a full
fledged research and development lab. With this, Zydus will now be able to manufacture
and distribute generic controlled substances in the US market, which otherwise cannot be
imported. The market for controlled substances medications in the US is
estimated at US$7bn.
The acquired ANDA pipeline comprising 8 existing filings and 5 products under
development present a tremendous market potential as they belong to high growth, niche
segments which have a combined estimated market size of over US$2.1bn. The agreement
also encompasses supply and technical services agreements by which certain products of
KV Pharmaceutical will be manufactured by Zynesher Pharmaceuticals USA LLC. Overall,
we remain positive on the deal and maintain our Buy rating with a target price of `1,053.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Zydus Cadila Healthcare Acquires US Company
Zydus Pharmaceuticals USA Inc., through its subsidiary Zynesher Pharmaceuticals USA LLC
has entered into an agreement to acquire the assets of the US based pharmaceutical
company Nesher Pharmaceuticals Inc. Nesher operates as the generic subsidiary of KV
Pharmaceutical,based at St. Louis, Missouri, USA. The financial details of the agreement
are undisclosed.
Nesher has considerable expertise in niche therapies which have development or
production barriers, such as controlled release medications or DEA-controlled substances.
The broad-based assets purchase agreement includes assets and assumption of certain
liabilities, Nesher’s existing and pipeline ANDAs, certain manufacturing facilities and a full
fledged research and development lab. With this, Zydus will now be able to manufacture
and distribute generic controlled substances in the US market, which otherwise cannot be
imported. The market for controlled substances medications in the US is
estimated at US$7bn.
The acquired ANDA pipeline comprising 8 existing filings and 5 products under
development present a tremendous market potential as they belong to high growth, niche
segments which have a combined estimated market size of over US$2.1bn. The agreement
also encompasses supply and technical services agreements by which certain products of
KV Pharmaceutical will be manufactured by Zynesher Pharmaceuticals USA LLC. Overall,
we remain positive on the deal and maintain our Buy rating with a target price of `1,053.
No comments:
Post a Comment